Explore the Potential with AI-Driven Innovation
This comprehensive focused library is produced on demand with state-of-the-art virtual screening and parameter assessment technology driven by Receptor.AI drug discovery platform. This approach outperforms traditional methods and provides higher-quality compounds with superior activity, selectivity and safety.
We carefully select specific compounds from a vast collection of over 60 billion molecules in virtual chemical space. Our partner Reaxense helps in synthesizing and delivering these compounds.
The library includes a list of the most promising modulators annotated with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Also, each compound is presented with its optimal docking poses, affinity scores, and activity scores, providing a comprehensive overview.
We employ our advanced, specialised process to create targeted libraries.
Fig. 1. The sreening workflow of Receptor.AI
Utilising molecular simulations, our approach thoroughly examines a wide array of proteins, tracking their conformational changes individually and within complexes. Ensemble virtual screening enables us to address conformational flexibility, revealing essential binding sites at functional regions and allosteric locations. Our rigorous analysis guarantees that no potential mechanism of action is overlooked, aiming to uncover new therapeutic targets and lead compounds across diverse biological functions.
Several key aspects differentiate our library:
partner
Reaxense
upacc
Q8TF64
UPID:
GIPC3_HUMAN
Alternative names:
-
Alternative UPACC:
Q8TF64; O75227
Background:
PDZ domain-containing protein GIPC3 plays a crucial role in the auditory system. It is essential for the postnatal maturation of the hair bundle, a key component in the mechanoelectrical transduction pathway for hearing. This protein ensures the long-term survival of hair cells and spiral ganglion, which are critical for sound perception.
Therapeutic significance:
GIPC3 is linked to Deafness, autosomal recessive, 15, a condition characterized by prelingual onset sensorineural hearing loss. Understanding the role of PDZ domain-containing protein GIPC3 could open doors to potential therapeutic strategies for this form of hearing impairment.